SUPN
SUPERNUS PHARMACEUTICALS, INC.Company Intelligence Hub
Filing history, signal momentum, and bull/bear evolution
Chronological Filing Evolution (Click to filter / toggle)
Thesis (Bull Case Evolution)
Supernus Pharmaceuticals is currently navigating a decisive commercial inflection point, transitioning from a niche CNS player into a diversified biopharmaceutical entity.…
Antithesis (Bear Case / Structural Risks)
Despite the headline revenue growth, a closer look at the financials reveals a troubling trend of generic erosion across legacy products. Sales of APOKYN plummeted 48%, while Trokendi XR and Oxtellar XR saw declines of 26% and 27% respectively.…
Read the full bull/bear analysis
You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SUPN filing.
Synthesis (Verdict & Resolution)
The Q1 2026 filing presents a company in a high-stakes transition. The integration of the Sage acquisition has provided an immediate revenue boost and a powerful new asset in ZURZUVAE, but it has also introduced significant amortization expenses and complex contingent liabilities. The shift toward a more diversified revenue stream is evident, yet the underlying struggle against generic competition in the legacy portfolio remains a persistent drag on the bottom line. Ultimately, the impact of this filing hinges on whether the growth of new products like ONAPGO and ZURZUVAE can outpace the decay of older assets and the rising costs of commercialization. While the cash position is strong, the looming threat of generic entry for Qelbree and the operational fragility of the ONAPGO supply chain suggest that the path to sustainable profitability is narrower than the bull case suggests. Investors must weigh the explosive potential of the new CNS pipeline against the systemic risks of litigation and supply chain instability.
Core Takeaway
Supernus is successfully diversifying its revenue via the Sage acquisition and Qelbree growth, but is fighting a losing battle against generic erosion in its older portfolio.
Investor Lens
The trade-off is between the high-growth potential of the new CNS pipeline and the accelerating decay of the legacy revenue base.
Watch Next
FDA approval and onboarding of the second supplier for ONAPGO expected in 2027.
Signal Momentum Chart
Quarterly net bull/bear signal ratio. Click nodes to select a quarter.
Signal Timeline
Filing History
The Q1 2026 filing presents a company in a high-stakes transition. The integration of the Sage acquisition has provided an immediate revenue boost and a powerful new asset in ZURZUVAE, but it has also introduced significant amortization expenses and complex contingent liabilities. The shift toward a more diversified revenue stream is evident, yet the underlying struggle against generic competition in the legacy portfolio remains a persistent drag on the bottom line. Ultimately, the impact of this filing hinges on whether the growth of new products like ONAPGO and ZURZUVAE can outpace the decay of older assets and the rising costs of commercialization. While the cash position is strong, the looming threat of generic entry for Qelbree and the operational fragility of the ONAPGO supply chain suggest that the path to sustainable profitability is narrower than the bull case suggests. Investors must weigh the explosive potential of the new CNS pipeline against the systemic risks of litigation and supply chain instability.
Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.